In a heartbreaking twist of fate, Maggie lost her own battle with breast cancer—the very disease she was fighting to defeat. Her dream, however, did not die with her.
It became our mission. In her honour, Pulmostics Limited was renamed Maggie’s Breath, reflecting both Maggie’s enduring legacy and the breath-based technology she believed in. Today, we are turning her vision into reality—creating a revolutionary, non-invasive screening tool that has the potential to save countless lives.
Maggie’s Breath was founded with a mission to develop a rapid, non-invasive, and painless screening system for breast cancer. Tragically, and with deep irony, the founder, Maggie Tham, lost her battle to the very disease she sought to improve screening for. In her honour, the company was renamed Maggie’s Breath, reflecting both her legacy and the breath-based technology at its core.
Originally incorporated as Pulmostics Limited, the company was established to develop an innovative diagnostic system for early breast cancer detection using breath analysis.
This vision led to the creation of BreathSense™ 1000—a first-of-its-kind, portable breath analysis system powered by patented technology and patent-pending algorithms.
During development, the technology was also found to have the potential to detect other cancers through volatile organic compound (VOC) analysis.
While the initial offering focuses on breast cancer detection, Maggie’s Breath is committed to expanding its capabilities, leveraging its proprietary innovations to revolutionize cancer screening and early diagnosis.
No radiation.
No discomfort.
No complex procedures.
Fast, affordable, and accurate.
Maggie’s Breath is pioneering a breath analysis to screen for breast cancer because it is the most common cancer in women today and women are the heart of the family. Breast Cancer is the first of many other cancers, lung cancer, liver cancer etc that can be detected through breath analysis and Maggie’s breath will develop detection algorithms for those.
First-of-its-kind portable breath analysis system – A game-changer in early cancer detection.
Patented technology & patent-pending algorithms – Unmatched accuracy and innovation.
Proven accuracy comparable to mammograms – Backed by peer-reviewed studies.
Low-cost, accessible solution – $20 per test, making early screening available to more people.
Potential to expand beyond breast cancer – Early research indicates efficacy in detecting other cancers.
Be among the first to experience the future of Cancer Screening.
Subscribe to our email list for updates on our progress, to see if you're eligible for our clinical trials, and be the first to access Maggie's breath when it launches. Button to click and fill in the contact details.